Comparison 12. Pimecrolimus 1.0% BID vs. pimecrolimus 1.0% QD, participants responding to pimecrolimus.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clear or almost clear eczema (IGA 0 or 1)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
1.1 8 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 16 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2 No flare of eczema	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2.1 16 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3 Withdrawals	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3.1 For any reason	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3.2 For lack of efficacy	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3.3 For adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4 Adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
4.1 Any adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.2 Skin infections	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]